Elisa R Port, MD
- ASSOCIATE PROFESSOR | Surgery
- Breast Cancer - Surgery
- Surgical Oncology
- Hospital Affiliations
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- Mount Sinai St. Luke's and Mount Sinai West
I am a surgeon who specializes in the care and treatment of patients with breast cancer, and those at increased risk for breast cancer. I have extensive experience with sentinel lymph node biopsy, nipple sparing mastectomy, and the newest techniques in breast cancer surgery for both invasive breast cancer and DCIS.
I am the author of a variety of publications on the role of sentinel lymph node biopsy in breast cancer, the role of MRI in patients at high risk for breast cancer, and I have received a Komen Foundation Grant investigating the role of PET scanning in breast cancer. I recently completed an NCI funded clinical trial investigating the effects of the COX2 inhibitor, Celebrex, on breast cancer tissue.
I am a member of many professional organizations including the Society of Surgical Oncology, the American Society of Breast Diseases, the American Society of Breast Surgeons, and the American College of Surgeons Oncology Group.
American Board of Surgery
BA, Dartmouth College
MD, Mount Sinai School of Medicine
Residency, General Surgery
Cedars-Sinai Medical Center
Residency, General Surgery
Long Island Jewish Medical Center
Fellowship, Research Fellow
Memorial Sloan Kettering Cancer Center
American College of Surgeons
Honors in Surgery
Mount Sinai School of Medicine
Third Honor Group
MRI in women at increased risk for breast cancer
Susan G. Komen Foundation Research Grant
Study of the role of Positron Emission Tomography (PET) scanning in the pre-operative management of patients with breast cancer
Applications of sentinel lymph node biopsy for breast cancer
NCI Sponsored Trial
Investigating COX-2 inhibition and aromatase activity in breast cancer
Port ER, Patil S, Stempel M, Morrow M, Cody HS. The Number of Nodes Removed in Sentinel Node-Negative Breast Cancer Patients is Significantly Related to Patient Age and Tumor Size: A New Source of Bias in Morbidity Assessment? . Cancer 2010 FEB;.
Chung A, Schoder H, Sampson M, Morrow M, Port ER. Incidental Breast Lesions Identified by 18F-Fluorodeoxyglucose-Positron Emission Tomography. . Ann Surg Oncol 2010 FEB;.
Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Flowers C, Troyan S, Garber J, Olopade O, Hylton N, Port ER, Campbell MC, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. . Breast Can Res Treat 2010; 119(1): 137-144.
Karam AK, Hsu M, Patil S, Stempel M, Traina TA, Ho AY, Cody HS, Port ER, Morrow M, Gemignani ML. Predictors of completion axillary lymph node dissection in patients with positive sentinel lymph nodes. . Ann Surg Oncol 2009 JUL; 16(7): 1952-1958.
Disa JJ, Port ER. More than 200,000 women will be diagnosed with breast cancer in 2008. . Cancer J. 2008; 14(4): 214-215.
Karam A, Stempel M, Cody III HS, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy.. J Am Coll Surg 2008 OCT; 207(4): 543-548.
Sacchini V, Beal K, Goldberg J, Montgomery L, Port ER, McCormick B. Study of quadrant high-dose intraoperative radiation therapy for early-stage breast cancer. . Br J Surg 2008 SEPT; 95(9): 1105-1110.
Flynn LW, Park J, Patil SM, Cody III HS, Port ER, . Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. . J Am Coll Surg 2008 APR; 206(4): 616-621.
Chan SW, LaVigne K, Port ER, Fey Jane V, Brogi E, Cody HS. Does the benefit of sentinel node frozen section vary between patients with invasive duct, invasive lobular and favorable histologic subtypes of breast cancer? . Ann Surg 2008 JAN; 247(1): 143-149.
Port ER, Garcia-Etienne CA, Park J, Fey J, Borgen PL, Cody HS. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. . Ann Surg Oncol. 2007 AUG; 14(8): 2209-2214.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Port did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.